Сomorbidity of obesity and dyspepsia in residents of Novosibirsk aged 35–54 years

The sensory and motor functions of the stomach, including gastric emptying and accommodation, leading to dyspepsia (D), significantly affect energy expenditure, and obesity is characterized by an energy imbalance. However, the data on the association of obesity and FD are heterogeneous. Aim: to assess the prevalence of obesity and D, its types, and to identify a possible association of D with obesity in a population sample (PS) aged 35–54 years. Material and methods. During 2023–2025, a random representative sample of 35–54-year-olds from one of the districts of the city is being surveyed on the basis of NIITPM. Novosibirsk. As part of the gastroenterological fragment, the PS examination of 192 persons (92 men and 100 women) included: gender, age, BMI, filling in the mFSSG D scale (a total score of 6 points corresponded to D). The results are presented as Me [Q25; Q75]. Results. The average age in PS in people with/without D, in men and women did not differ. The prevalence of D in PS (n = 192) was 26.04 % (n = 50), in women – 64.00 %, in men – 36.00 % (p < 0.05). The prevalence of two types of FD: epigastric pain syndrome (EPS) is 24.00 %, and postprandial distress syndrome (PРDS) is 76.00 % (p < 0.05). The prevalence of obesity in the PS of people without D was 24.82%, with D – 32.00 % (p > 0.05). The BMI in individuals with PРDS – 27.54 [23.78; 32.96] kg/m2 exceeded the BMI in individuals with EPS – 23.56 [22.19; 27.02] kg/m2 (p < 0.05). Obesity is associated with the presence of PРDS (rSpearmen = +0.48, p < 0.05). In PS, no association was found between the presence of D and obesity, but among people over 53 years of age with obesity, D was observed 11.2 times more often than in people with normal body mass (p = 0.037). Conclusions. In PS in Novosibirsk, 35–54 years old, D is characterized by a high prevalence, and in women it is 1.78 times higher than in men; PPDS dominates in the D patients. The prevalence of obesity in PS in people with and without D did not differ, however, an association of obesity with D was found in people over 53 years and in people with PPDS.

1. Busebee B., Ghusn W., Cifuentes L., Acosta A. Obesity: a review of pathophysiology and classification. Mayo Clin. Proc., 2023; 98 (12): 1842–1857. doi: 10.1016/j.mayocp.2023.05.026

2. Csige I., Ujvárosy D., Szabó Z., Lőrincz I., Paragh G., Harangi M., Somodi S. The impact of obesity on the cardiovascular system. J. Diabetes Res., 2018; 2018: 3407306. doi: 10.1155/2018/3407306

3. McGill H.C., McMahan C.A., Herderick E.E., Zieske A.W., Malcom G.T., Tracy R.E., Strong J.P. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation, 2002; 105 (23): 2712–2718. doi: 10.1161/01.cir.0000018121.67607.ce

4. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nature Reviews Cardiology, 2009; 6 (6): 399–409. doi: 10.1038/nrcardio.2009.55

5. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., Kiprianis V.A., Okhlobystina O.Z. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2017; 27 (1): 50–61. (In Russ.)]. doi: 10.22416/1382-43762017-27-1-50-61

6. Sayuk G.S., Gyawali C.P. Functional dyspepsia: diagnostic and therapeutic approaches. Drugs, 2020; 80 (13): 1319–1336. doi: 10.1007/s40265-020-01362-4

7. Emerenziani S., Guarino M.P.L., Trillo Asensio L.M., Altomare A., Ribolsi M., Balestrieri P., Cicala M. Role of overweight and obesity in gastrointestinal disease. Nutrients, 2019; 12 (1): 111. doi: 10.3390/ nu12010111

8. Vona R., Pallotta L., Cappelletti M., Severi C., Matarrese P. The impact of oxidative stress in human pathology: focus on gastrointestinal disorders. Antioxidants (Basel), 2021; 10 (2): 201. doi: 10.3390/ antiox10020201

9. Scirocco A., Pallotta L., Rengo M., Ignazzi A., Carabotti M., Cicenia A., Vona R., Chirletti P., Maselli M.A., Donghia R., Coluzzi M., Matarrese P., Silecchia G., Severi C. Myogenic oxidative imbalance interferes with antral motility in obese subjects. Dig. Liver Dis., 2018; 50 (8): 820–827. doi: 10.1016/j. dld.2018.03.005

10. Trujillo-Benavides O.E., Rojas-Vargas E.E. Influence of obesity on dyspepsia symptoms. Rev. Gastroenterol. Mex., 2010; 75 (3): 247–252.

11. Yamamoto Y., Furukawa S., Watanabe J., Kato A., Kusumoto K., Takeshita E., Ikeda Y., Yamamoto N., Kohara K., Saeki Y., Hiasa Y. Association between body mass index and functional dyspepsia in young japanese. J. Neurogastroenterol. Motil., 2022; 28 (2): 276–282. doi: 10.5056/jnm21076

12. Kusano M., Shimoyama Y., Sugimoto S., Kawamura O., Maeda M., Minashi K., Kuribayashi S., Higuchi T., Zai H., Ino K., Horikoshi T., Sugiyama T., Toki M., Ohwada T., Mori M. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J. Gastroenterol., 2004; 39 (9): 888–891.

13. Kusano M., Hosaka H., Kawamura O., Kawada A., Kuribayashi S., Shimoyama Y., Yasuoka H., Mizuide M., Tomizawa T., Sagawa T., Sato K., Yamada M. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive GERD during maintenance PPI therapy. J. Gastroenterol., 2015; 50 (3): 298–304. doi: 10.1007/ s00535-014-0972-9

14. Mayanagi S., Kishino M., Kitagawa Y., Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to protonpump inhibitor monotherapy. Tohoku J. Exp. Med., 2014; 234 (3): 237–240. doi: 10.1620/tjem.234.237

15. Lazebnik L.B., Lyalyukova E.A., Alexeenko S.A., Samsonov A.A., Serebrova S.Yu., Tsukanov V.V., Kareva E.N. Diagnostic evaluation of patient with dyspepsia syndrome and heartburn by gp and primary care physician: need of a new & simple questionnaire. Experimental and Clinical Gastroenterology, 2018; (2): 167–173. (In Russ.)].

16. Ford A.C., Marwaha A., Sood R., Moayyedi P. Global prevalence of, and risk factors for uninvestigated dyspepsia: a meta-analysis. Gut, 2015; 64: 1049–1057. doi: 10.1136/gutjnl-2014-307843

17. Drossman D.A., Li Z., Andruzzi E., Temple R.D., Talley N.J., Thompson W.G., Whitehead W.E., Janssens J., Funch-Jensen P., Corazziari E., Richter J.E., Koch G.G. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci., 1993; 38 (9): 1569–1580. doi: 10.1007/BF01303162

18. Haque M., Wyeth J.W., Stace N.H., Talley N.J., Green R. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. NZ Med. J., 2000; 113 (1110): 178–181.

19. Chowdhury J., Islam M.S., Miah A.R., Saha A., Pal P., Siddique A.A., Alam M.S., Raihan M.A. Study of the prevalence of dyspepsia in the adult population in a rural community of Bangladesh. Mymensingh. Med. J., 2019; 28 (1): 163–174.

20. Ford A.C., Mahadeva S., Carbone M.F., Lacy B.E., Talley N.J. Functional dyspepsia. Lancet, 2020; 396 (10263): 1689–1702. doi: 10.1016/S01406736(20)30469-4

21. Dakubo J.C., Clegg-Lamptey J.N., Sowah P. Appropriateness of referrals for upper gastrointestinal endoscopy. West. Afr. J. Med., 2011; 30 (5): 342–347.

22. Nasseri-Moghaddam S., Mousavian A.H., Kasaeian A., Kanno T., Yuan Y., Ford A.C., Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Updated systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2023; 21 (7): 1739–1749.e2. doi: 10.1016/j.cgh.2022.05.041

23. Vinson B., Fink C., Wargenau M., Talley N.J., Holtmann G. Double-blind, randomized, 8-week multicenter study of the efficacy and safety of STW 5-II versus placebo in functional dyspepsia. JGH Open., 2024; 8 (5): e13054. doi: 10.1002/jgh3.13054

24. Barberio B., Mahadeva S., Black C.J., Savarino E.V., Ford A.C. Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Aliment. Pharmacol. Ther., 2020; 52 (5): 762–773. doi: 10.1111/apt.16006

25. Santonicola A., Gagliardi M., Asparago G., Carpinelli L., Angrisani L., Iovino P. Anhedonia and functional dyspepsia in obese patients: Relationship with binge eating behaviour. World J. Gastroenterol., 2020; 26 (20): 2632–2644. doi: 10.3748/wjg.v26.i20.2632

26. Camilleri M., Dubois D., Coulie B., Jones M., Kahrilas P.J., Rentz A.M., Sonnenberg A., Stanghellini V., Stewart W.F., Tack J., Talley N.J., Whitehead W., Revicki D.A. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin. Gastroenterol. Hepatol., 2005; 3: 543–552. doi: 10.1016/S1542-3565(05)00153-9

27. Camilleri M. The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions. Neurogastroenterol. Motil., 2024; 36 (2): e14660. doi: 10.1111/nmo.14660

28. Park M.I., Camilleri M., O’Connor H., Oenning L., Burton D., Stephens D., Zinsmeister A.R. Effect of different macronutrients in excess on gastric sensory and motor functions and appetite in normal-weight, overweight, and obese humans. Am. J. Clin. Nutr., 2007; 85 (2): 411–418. doi: 10.1093/ajcn/85.2.411

29. Hunt R.H., Camilleri M., Crowe S.E., ElOmar E.M., Fox J.G., Kuipers E.J., Malfertheiner P., McColl K.E., Pritchard D.M., Rugge M., Sonnenberg A., Sugano K., Tack J. The stomach in health and disease. Gut, 2015; 64 (10): 1650–1668. doi: 10.1136/gutjnl-2014-307595

30. Maisiyiti A., Chen J.D. Systematic review on gastric electrical stimulation in obesity treatment. Expert. Rev. Med. Devices, 2019; 16 (10): 855–861. doi: 10.1080/17434440.2019.1673728

31. Park M.I., Camilleri M. Gastric motor and sensory functions in obesity. Obes. Res., 2005; 13 (3): 491– 500. doi: 10.1038/oby.2005.51

32. Pajot G., Camilleri M., Calderon G., Davis J., Eckert D., Burton D., Acosta A. Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study. Int. J. Obes. (Lond), 2020; 44 (12): 2472–2478. doi: 10.1038/s41366-020-0593-8

33. Pan X., Jia Z., Zhen R., Yue L., Niu S., Ban J., Chen S. mechanisms of small intestine involvement in obesity-induced atherosclerosis. Diabetes Metab. Syndr. Obes., 2023; 16: 1941–1952. doi: 10.2147/ DMSO.S421650

34. Acosta A., Camilleri M., Shin A., VazquezRoque M.I., Iturrino J., Burton D., O’Neill J., Eckert D., Zinsmeister A.R. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology, 2015; 148 (3): 537–546.e4. doi: 10.1053/j.gastro.2014.11.020

35. Grigor’eva I.N., Romanova T.I., Suvorova T.S., Nepomnyashchikh D.L. Metformin and intestinal microbiota. Medical Alphabet, 2024; (26): 19–23. (In Russ.)]. doi: 10.33667/2078-5631-2024-26-19-23